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Alzheimer’s disease mutations in APP but not
g-secretase modulators affect epsilon-cleavage-
dependent AICD production
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Pathological amino-acid substitutions in the amyloid precursor protein (APP) and chemical
g-secretase modulators affect the processing of APP by the g-secretase complex and the
production of the amyloid-beta peptide Ab42, the accumulation of which is considered
causative of Alzheimer’s disease. Here we demonstrate that mutations in the transmembrane
domain of APP causing aggressive early-onset familial Alzheimer’s disease affect both g- and
e-cleavage sites, by raising the Ab42/40 ratio and inhibiting the production of AICD50–99,
one of the two physiological APP intracellular domains (ICDs). This is in sharp contrast to
g-secretase modulators, which shift Ab42 production towards the shorter Ab38, but
unequivocally spare the e-site and APP- and Notch-ICDs production. Molecular simulations
suggest that familial Alzheimer’s disease mutations modulate the ﬂexibility of the APP
transmembrane domain and the presentation of its g-site, modifying at the same time, the
solvation of the e-site.
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T
he main pathological hallmark of Alzheimer’s disease (AD)
is the formation of toxic amyloid ﬁbres that progressively
accumulate into plaques, which leads to degeneration of
the neighbouring neuronal cells1. Further biochemical studies
identiﬁed the main protein component of plaques to be a short
fragment of amyloid precursor protein (APP), the 42-amino acid
long peptide Ab42 (ref. 2). Moreover, dominantly inherited
mutations causing familial Alzheimer’s disease (FAD) are found
in APP as well as in the PSEN1 and PSEN2 (refs 3,4) genes
encoding for the catalytic subunit of the g-secretase complex, an
intramembrane-cleaving protease that cleaves APP in the plasma
membrane and generates the Ab peptides5. Together, these
ﬁndings clearly demonstrated the implication of APP, g-secretase
and Ab in both the sporadic and genetic forms of AD. They
further highlighted the g-secretase-dependent APP processing as
an attractive target for drug development.
In addition to APP, g-secretase cleaves various other substrates
regulating biological functions including development and stem
cell differentiation. This unusual proteolytic complex indeed has
an important role in cell signalling pathways by processing
different type-I transmembrane cell receptors including the Notch
receptors, the Insulin receptor and the Growth hormone receptor6.
In the brain, it maintains synaptic contacts by regulating cleavage
of neuronal adhesion molecules like Cadherins and Neurexins7,8.
With the continuously growing number of substrates the need for
understanding the exact molecular mechanism of this particular
proteolytic processing arises.
g-Secretase is composed of four subunits, presenilin (PS), Aph-
1, Pen-2 and Nicastrin (NCT). The complex contains a total of 19
a-helices embedded in the membrane bilayer, which allows the
overall structure to adopt different conformations upon binding
with the substrate or different chemical compounds9,10.
Moreover, the catalytic aspartate residues (Asp257/385) in hPS1
are buried into the lipid bilayer and surrounded by hydrophobic
helices and the electron microscopy density maps suggested the
existence of two pores in the globular structure of g-secretase,
which can explain the entrance of water molecules necessary for
the hydrolysis of the peptide bond11. Yet, a rigorous biochemical
characterization of g-secretase complexes with FAD mutations
revealed that they all represent a loss of enzymatic function, but
they ultimately lead to altered Ab production and elevated Ab42/
40 ratio12,13. Interestingly, FAD mutations in APP can show
substrate cleavage patterns that differ from those of the mutations
in g-secretase. In the processing of APP, its large extracellular
domain is ﬁrst removed by b-secretase in the vicinity of the
plasma membrane (Fig. 1). Gain-of-function mutations in this b-
site cause elevated levels of total Ab14. g-Secretase processes the
remaining 99-amino-acid APP-C-terminal fragment (APP-C99)
at e-sites close to the inner layer of the membrane, and releases
49- and 50-amino-acid long APP intracellular domains
(AICD50–99 and AICD49–99; Fig. 1). After this step, g-
secretase sequentially continues to trim the residual
transmembrane stub, ﬁnally producing Ab42, Ab40 and Ab38
peptides15 (Fig. 1). Mutations surrounding the e-sites either
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Figure 1 | Sequential proteolytic processing of APP by b- and c-secretases. Full-length APP is initially cleaved by b-secretase, liberating a soluble APPb
(sAPPb) into the extracellular space. The remaining 99-amino-acid long transmembrane APP-C99 is further processed by g-secretase at e-sites, close to
the inner layer of the membrane, releasing two APP intracellular signalling domains (AICDs) differing by one amino acid in length, AICD49–99 and
AICD50–99. These products are in nearly equimolar ratio as depicted in the representative mass spectrometry AICD proﬁle. Next, g-secretase continues to
trim the residual membrane-embedded N-terminal fragment at g-sites, ﬁnally generating Ab peptides secreted into the extracellular space. In contrast to
equimolar AICD production, mass spectrometric analysis of secreted Ab shows that Ab40 is in large excess when compared to the more amyloidogenic
Ab42 directly involved in the pathogenesis of AD through the formation of Ab plaques.
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increase the production of Ab42, which is more neurotoxic
compared to the shorter and less ﬁbrillogenic Ab40 or lead to
elevated total amounts of the Ab product without affecting Ab
ratios13,16. Amino-acid substitutions in the g-site lead to high
Ab42/40 ratios and are characterized by the most prominent and
earliest phenotypes of FAD17.
Inhibiting the g-secretase activity to reduce Ab production
is an attractive therapeutic strategy to treat AD. However,
g-secretase inhibitors (GSIs) tested in clinical trials not only failed
to meet their initial clinical endpoints, but also manifested severe
off-target effects due to impaired Notch signalling, leading to
gastrointestinal bleeding and increased risk of skin cancer18.
Consequently, a concept of selective modulation of the
g-secretase activity has emerged. A subset of non-steroidal anti-
inﬂammatory drugs (NSAIDs) were the ﬁrst Notch-sparing small
molecules shown to selectively lower Ab42 and subsequently raise
Ab38 both in vitro and in vivo19,20. These g-secretase modulators
(GSMs) were initially shown to bind to APP, although some more
recent studies demonstrated that they also can target
g-secretase21,22. Although the precise molecular mechanism of
action remains poorly understood, a number of these molecules
have advanced to clinical trials23.
In this report, we demonstrate that second generation GSMs,
including the clinically tested E2012, effectively lower the
production of toxic Ab42 without affecting the e-cleavage sites
of both APP and Notch substrates. In contrast, we show that the
T714I, V715A, V717F and L723P FAD-APP mutations in the
transmembrane (TM) region block the production of AICD50–
99, the 49-amino-acid long AICD, without affecting the total
amount of AICD. Moreover, mutations T714I and V715A elevate
the Ab42/40 and Ab38/40 ratios, in contrast to I716V, V717F and
L723P for which these proﬁles were comparable to those obtained
with wild-type APP. GSMs affect all mutants at their g-cleavage
site, with the strongest effect on the Ab38/40 and Ab42/40 ratios
in T714I and V715A, suggesting that these amino-acid substitu-
tions are important for the generation of Ab42 and Ab38. In
addition, we ﬁnd that GSMs do not reverse the loss of AICD50–
99 production caused by FAD mutations. We rationalize these
ﬁndings using molecular dynamic simulations of the APP TM
segment embedded in the lipid bilayer, and propose that FAD-
APP mutants and possibly GSMs affect the g-cleavage site by
changing the ﬂexibility, tilt angle and position of the substrate in
the membrane. GSMs fail to recover e-cleavage, most likely
because they affect the substrate–enzyme interface at a position
that is distant from the e-site and closer to the outer layer of the
membrane. Finally, FAD mutants have altered solvation at the
e-cleavage site, which can explain the different product lines
generated after the ﬁrst step of the processing of APP.
Results
GSMs affect the c- but not the e-cleavage of APP and Notch.
We ﬁrst investigated the effect of GSM-1 and E2012, two repre-
sentative molecules of the two main classes of second generation
GSMs: NSAID-based phenylpiperidine-type compounds and
non-NSAID bridged aromatics, respectively (Fig. 2a). Although
these compounds have different structures, they both modulate
g-secretase activity at low nanomolar concentrations in cells24. In
enzymatic in vitro assays using highly puriﬁed g-secretase and
recombinant APP-C100-Flag substrate, we ﬁrst show that
concentrations several fold higher than the cellular IC50 values
of GSM-1 and E2012 do not affect the overall amounts of Ab and
AICD, when compared to control levels (Fig. 2b, upper panels
and Supplementary Fig. S1). We next investigated in detail the
effect of these molecules on all reaction products. For both
compounds tested at 10 mM, immunoprecipitation with 4G8 anti-
Ab antibody, combined with MALDI-TOF spectrometry (IP/MS)
revealed a robust increase of Ab38/40 ratio, associated with a
decrease in Ab42/40 ratio (Fig. 2b, middle panels). At this
concentration, GSM-1 showed a stronger effect than E2012 on
Ab42/40 and Ab38/40 ratios, while both compounds lowered
Ab43/40 ratio. IP/MS analyses of the C-terminal cleavage
products revealed an unchanged equimolar production of the
two AICDs (Fig. 2b, lower panels). Together, these results clearly
demonstrate that GSMs affect the APP g-cleavage sites, whereas
they completely spare the e-sites. Because of the clinical relevance
of GSMs and the Notch signalling pathway, we further
investigated whether GSMs could interfere with the Notch
intracellular domain (NICD) production. As shown in Fig. 2c,
GSMs did not inﬂuence total NICD production and did not affect
the NICD cleavage proﬁles. Our in vitro ﬁndings were further
conﬁrmed in cell-based assays. First, intracellular accumulation of
endogenous g-secretase substrates APP-C83 and APP-C99, which
is a common characteristic among known g-secretase substrates
in response to g-secretase inhibition, was assessed in HEK293T
cells stably overexpressing APP with the FAD Swedish mutation
KM670/671NL. In contrast to the control GSI, 1 and 10 mM
E2012 or GSM-1 did not affect the levels of APP-CTFs
(Supplementary Fig. S2a). Next, treatments with E2012 and
GSM-1 up to 1 mM in a cell-based luciferase assay, in which AICD
generation correlates with increased luciferase expression and
induced luminescence emission, did not result in a signiﬁcant
inhibition of AICD release (Supplementary Fig. S2b).
Additionally, the GSMs were tested in human lymphocytic
leukaemia SUP-T1 cells constitutively producing NICD. In
contrast to the GSI XIX that completely abolished NICD
production, E2012 and GSM-1 did not affect NICD production
at concentrations up to 10 mM (Supplementary Fig. S3a). These
ﬁndings were conﬁrmed in a cellular Notch-based assay in which
a luciferase reporter system is directly placed under the control of
NICD (Supplementary Fig. S3b), as well as in RPMI8402 (ref. 25)
cells expressing a mutated Notch-1 receptor, which makes the
receptor susceptible to constitutive cleavage by g-secretase in a
ligand-independent manner (Supplementary Fig. S3c). In the
latter two assays, E2012 and GSM-1 concentrations up to 1 mM
did not affect NICD production. At 10mM, E2012, but not
GSM-1, signiﬁcantly reduced NICD production in DL4-Hela/N1-
Hela co-cultures by 55% (***Po0.001,Supplementary Fig. S3b).
Taken together, we conclude that E2012 and GSM-1 do not alter
the Notch and APP e-site cleavage at concentrations as high
as 10-fold cellular IC50. At higher concentrations (B100-fold
cellular IC50), only the non-NSAID-based compound E2012 can
inhibit to some extent intracellular signalling of Notch and APP
in cell-based assays.
APP mutations differentially alter c- and e-sites. APP muta-
tions causing FAD can be grouped based on their localization at
three different regions: at the b-secretase cleavage site, in close
vicinity of the a-secretase cleavage site in the Ab region or in the
transmembrane domain (TMD) of APP, between the g- and the
e-sites (Fig. 3a, left). These mutations differ not only by the onset
of the disease (Fig. 3a, right), but also by the molecular ﬁngerprint
of the produced Ab peptides. Indeed, the vast majority of
mutations in the a-and b-sites lead to the overproduction of total
Ab (mutations in the Ab region can also render the Ab42 peptide
more ﬁbrinogenic and prone to aggregation), while mutations in
the transmembrane region seem to be linked to an elevated Ab42/
40 ratio13,26. As no information exists about how these mutations
affect both the g- and e-cleavage sites in APP, and because AICD
has been suspected to have a role in the pathogenesis of AD, we
analysed Ab and AICD products generated from puriﬁed His6-
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tagged APP-C99 substrates carrying the FAD mutations listed
in Fig. 3a. As shown in Supplementary Figs S4 and S5, we ﬁrst
veriﬁed that His6- and Flag-tagged substrates respond to GSM
treatments in an identical manner, conﬁrming that different tags
(His6 or Flag) do not affect either the proﬁles of g- and e-site
products (Supplementary Fig. S4), or the overall production of
Ab or AICD (Supplementary Fig. S5). Next, IP/MS analyses of the
Ab and AICD proﬁles revealed that amino-acid substitutions
clustered near the a-secretase (A692G, E693G and D694N)
apparently do not alter the Ab or AICD proﬁles, when compared
to the control WT APP-C99 (Fig. 3b and Table 1). In striking
contrast, T714I and V715A mutations close to the
transmembrane g-cleavage site lead to drastically increased
Ab42/40 and Ab38/40 ratios and to a total inhibition of the
production of the shortest AICD50–99 (Fig. 3b,c and Table 1).
Interestingly, mutations closer to the e-cleavage sites (I716V,
V717F and L723P) are characterized by an intermediate
phenotype as they do not alter Ab proﬁles, but clearly lower
the production of AICD50–99 (below detection levels for V717F
and L723P; Fig. 3b,c and Table 1). Taken together, our data
demonstrate that FAD-causing mutations in the transmembrane
region of APP, but not close to the a-secretase site, affect both
g- and/or e-sites (summarized in Table 1).
GSMs affect the c- but not the e-cleavage of APP. To better
understand the molecular mechanism by which GSMs shift Ab
production, as well as to verify whether GSMs can still lower
Ab42 and have potential therapeutic beneﬁts in patients with
FAD, we decided to test GSM-1 on APP-C99 with FAD muta-
tions. GSM-1 was chosen because it was more potent in our
in vitro g-secretase assay, and also because this compound did
not affect e-cleavage in all cell-based experiments. First, 10 mM
GSM-1 did not affect the levels of total cleavage products
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Figure 2 | GSMs alter c-site processing but do not modulate e-site on APP-C99-Flag and NotchDE-Flag in vitro by highly puriﬁed c-secretase.
(a) Chemical structure of clinically tested small molecules NSAID-based phenylpiperidine-type GSM-1 and bridged aromatics E2012. (b) GSMs do not
inhibit the overall cell-free processing of APP-C99-Flag as shown by WB analysis of Ab and AICD at concentrations ranging from low nanomolar to low
micromolar. Following immunoprecipitation, analysis by MALDI-TOF demonstrated the efﬁcacy of GSMs on the g-site, where they shifted the production
towards shorter Ab38 and lowered Ab42. Even at concentrations as high as 10mM, GSMs do not alter the e-site as evidenced by the IP/MS on the AICD
products, AICD49–99 and AICD50–99. (c) GSMs show no inhibition on Notch intracellular signalling products. In vitro NICD formation from NotchDE-Flag
as detected by WB is unaltered. The ratio of the two NICD products, NICD1744-1809 and NICD1743-1809, detected after IP/MS, also remained without
change in the presence of 10mM of both compounds.
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Figure 3 | Pathological mutations in APP cause altered processing at both e- and c-sites. (a) FAD-APP mutations differ by the onset, but are all
clustered close to the a-secretase and g-secretase cleavage sites, as represented schematically in the left panel (colour coding: a-secretase site mutations
in green; g-secretase site mutations in red). Different mean onsets are summarized in the right table. The earliest onset is reported for Austrian and
German families at the age of 34 and 47 years, respectively. (b) IP/MS proﬁles of Ab generated from puriﬁed His-tagged FAD-APP-C99 substrates show
that mutations A692G, E693G, D694N, I716V, V717F and L723P have similar and WT-like Ab38/40 and Ab42/40 ratios. In contrast, T714I and V715A
mutations in the transmembrane region led to a drastic increase in both Ab38/40 and Ab42/40 ratios. (c) AICD proﬁles from the same reactions
as analysed by IP/MS. FAD-APP-C99 mutations close to the a-secretase site produce AICD49–99 and AICD50–99 in nearly equimolar ratios. Amino-acid
substitutions in close vicinity of the g-sites in the TMD strongly affect the yield of shorter AICD50–99.
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(compare AICD and Ab levels in Supplementary Figs S4a and
S5b), providing further evidence that GSMs do not modify the
overall yield of g-secretase processing. Next, we found that GSM-
1 conserved its Ab42-lowering and Ab38-raising properties on all
tested mutant substrates (Fig. 4a). However, GSM-1 did not
inﬂuence the e-cleavage and none of the mutants tested recovered
the wild-type phenotype of nearly equimolar production
of AICD49–99 and AICD50–99 (compare AICD proﬁles in
Figs 4b and 3c, and see estimations of AICD 49–99/AICD50–99
ratios in Table 2). Our ﬁndings provide new evidence that GSMs
lower Ab42/40 ratio production by interfering with the g-site in
APP substrates with FAD mutations, strongly suggesting that
none of the substituted amino-acid residues are crucial for the
GSM-dependent modulation of APP processing by g-secretase.
They further demonstrate that GSMs do not affect the e-cleavage
site and thus fail to reverse the effects on AICD production of
FAD-causing mutations in the transmembrane domain of APP
(summarized in Table 2).
Structural changes in the TM domain of APP. To support our
results mechanistically, we used molecular dynamic (MD)
simulations to gain further insights into the structural and
dynamic properties of the TMD of wild-type APP and three FAD
mutants (T714I, V715A and V717F) in the membrane environ-
ment. These mutations were chosen because they affect either
both g- and e-cleavage sites (T714I and V715A), or exclusively
the e-site (V717F). As g-secretase activity assays performed with
puriﬁed enzyme and APP-C99 substrate reconstituted in PCþ PE
(phosphatidyl choline and phophatidylethanolamine) or PC alone
revealed almost identical IP/MS proﬁles of Ab and AICDs
(Supplementary Fig. S6), the TM region of the APP-C99 NMR
structure (PDB code 2LP1 (ref. 27)) was used and inserted into a
palmitoyl oleoyl phosphatidyl choline (POPC) lipid bilayer
(Fig. 5a). Thus, MD simulations were carried out under physio-
logical-like conditions (that is, pHB7, 1 atm, 300K), mimicking
as closely as possible the conditions of the g-secretase enzymatic
assay used in our study. For all systems, the secondary structure
of the APP ﬂuctuated only marginally. Consistent with the NMR
observations, the N terminus amphiphilic helix (Q686–N698) lies
on the membrane surface, whereas a lysine belt (K687, K699 and
K724–726) anchors the TMD and N terminus helices, respec-
tively, in and onto the membrane (Fig. 5a). During simulation,
the helices tilted with respect to the membrane surface. We found
that the V717F mutation affected the orientation of the TMD the
most, tilting it by 45±5, whereas the wild type and T714I and
V715A mutants remained more vertical (36±5, 38±3 and
36±3, respectively) (Fig. 5a and Supplementary Fig. S7a). These
mutations further shifted the TMD perpendicularly to the
membrane surface. When measuring the position of the Ab42
cleavage site (that is, I712–A713 peptide bond), the T714I and
V715A mutants shifted closer (2.9±1.2 Å and 2.3±0.9 Å,
respectively) to the cytoplasmic interface compared to the WT,
whereas V717F moved closer ( 0.2±1.3 Å) to the extracellular
membrane layer (Fig. 5b). The combined effect of shifting and
tilting perturbations of the APP TMD is due to FAD mutations.
This probably affects the presentation of the g-cleavage site at
position 42 to the enzyme and correlates quantitatively with the
changes in the Ab42/Ab40 ratio. Moreover, the ﬂexibility of the
transmembrane domain, which was estimated based on the local
bending of the helix28, was much higher for the T714I and V715A
mutants, speciﬁcally at the G700XXXG704XXXG708 region
(Fig. 5c). Molecular docking and simulations of the GSM-1
compound suggest the same region to be the conserved drug-
binding pocket for the wild-type and mutant APPs
(Supplementary Fig. S7b). In the drug-binding pocket, L701,
G704 and G708 had the most direct interactions with GSM-1.
Thus, the effect of GSM-1 on T714I and V715A FAD mutants
might cause a reduction of their ﬂexibility close to the g-site. For
all three mutants, the hydration of the e-site at residue L720
signiﬁcantly decreased compared to the WT (Fig. 5d). In
particular, for APP-WT, one water molecule is on an average
within 3Å of L720 backbone, the water coordination number
drops to o0.5 Å for V715A, and to nearly zero for T714I and
V717F. This effect is related to the different water permeation
properties of the APP C terminus lysine belt combined with the
perturbed helical orientation produced by the mutants. In
summary, our data support a model in which structural
changes, particularly the position of the g-cleavage site relative
to the membrane surface, can potentially modulate Ab
production. In this model the hydration of L720 can affect the
e-cleavage site and the production of the two amyloid precursor
protein intracellular domains potentially implicated in signalling
pathways and in the pathogenesis of AD.
Discussion
Mutations in APP cause aggressive early-onset AD by triggering
abnormal production, accumulation and aggregation of Ab
peptides. The most severe pathological phenotype is observed
for mutations occurring in the transmembrane region and in
close vicinity of the Ab42 g-cleavage site, leading to elevated
Ab42/40 and Ab38/40 ratios (Fig. 3). Small chemical g-GSMs are
known to lower Ab42 and raise Ab38, without affecting the
overall production of the Ab peptides. In this study, we used
second generation GSMs with a strong therapeutic potential
(GSM-1 and E2012), in combination with APP substrates with
FAD-causing mutations, to better understand the molecular
mechanisms of the g-secretase-dependent, intramembrane and
sequential cleavage of the substrate; to identify changes in APP
cleavage proﬁles, potentially implicated in the pathogenesis of
AD; and to further support the therapeutic potential of GSMs to
safely treat sporadic as well as early-onset familial AD. We further
demonstrate here that GSMs represent an attractive scaffold for
structure–activity relationship design of potent disease-modifying
drugs against AD. As they do not affect the processing of the
Notch substrate (Fig. 2), GSMs are expected to circumvent
clinical side effects observed with GSIs and attributed to impaired
Notch processing18. Moreover GSMs do not alter AICD
production (Fig. 2) and thus are not likely to inﬂuence the
downstream cell signalling functions of APP, again underlying
the huge therapeutic potential of these compounds in sporadic
AD cases. Additionally, our results conﬁrm altered g-site
Table 1 | Summary of the apparent ratios from the different
c- and e-site products.
Apparent ratios
Mutation Ab 38/40 Ab 42/40 Ab 38/42 AICD 49–99/50–99
WT 0.11 0.16 0.6 1
A692G 0.15 0.25 0.6 1.02
E693G 0.22 0.11 2 1
D694N 0.23 0.11 2 0.91
T714I 1.33 0.6 2 0.17
V715A 0.5 0.6 0.75 0.21
I716V 0.13 0.11 1.25 0.71
V717F 0.22 0.16 1.33 o0.1
L723P 0.38 0.22 1.75 o0.1
Ratios are estimated from peak intensities determined by MALDI-TOF analysis with respect to
Fig. 3.
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processing in APP T714I and V715A mutations13, associated with
an increase of Ab42/40 and Ab38/40 ratios and demonstrate that
mutations located in close vicinity to the g-site do impede the
production of the shorter e-site counterpart AICD50–99. Our
novel ﬁndings shed light on the effect of GSMs on the generation
of all Ab and AICD species from APP-WT and APP-FAD. In our
study, we have further investigated the effect of GSMs on the
g- and e-site APP cleavage products. Our results show that none
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Figure 4 | GSMs potently shift the production at c- and not at e-sites in APP with FAD mutations. (a) IP/MS proﬁles of Ab species produced from
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of the amino-acid residues of APP-WT causing FAD when
mutated are critically implicated in the mechanism of action of
GSMs in shifting the production from Ab42 to Ab38. Next, we
demonstrate that GSMs are not involved in the ﬁrst step of the
sequential proteolytic model15 because they do not modulate the
e-site products (AICD50–99 and AICD49–99) of the enzymatic
reaction. Interestingly, mutations T714I and V715A display the
strongest phenotype at both g- and e-sites, with highest Ab42/40
and Ab38/40 ratios (Table 1). Moreover, these mutations lead to
the production of only one detectable AICD, suggesting a putative
role of AICD in AD pathogenesis. These results might be
explained with the sequential cleavage model of APP-CTF, in
which the generation of Ab40 is dependent on the AICD50–99,
while Ab42/38 is linked to AICD49–99 (ref. 15). Based on this
model, reduced AICD50–99 (as observed for some FAD mutants)
is expected to be associated with less Ab40 and more Ab42/38,
thus increasing the pathogenic ratio of Ab42/40. The
combination of higher Ab42/40 ratio and the loss of AICD50–
99 can explain the extreme aggressiveness of these APP mutations
with regard to the onset of the disease. GSMs were still potent
at the g-site of mutated APP substrates (Fig. 4), as expected
from molecular docking and simulations suggesting the
G700XXXG704XXXG708 region as a possible GSM-binding
pocket (Supplementary Fig. S7b). GSMs have also been shown
to target PS1-NTF9,22,29, supporting the hypothesis that these
compounds could bind at the interface between APP-C99 and the
substrate-docking site of g-secretase. Moreover, the region
between g- and e-sites on APP-CTF has been proposed to be a
binding domain for PS1-NTF30, and peptides mimicking this
domain can selectively block Ab production, sparing Notch
processing31. Together, these ﬁndings clearly demonstrate that
GSMs can be used for the treatment of patients with both
sporadic and genetic forms of AD.
Table 2 | Summary of the apparent ratios from the different
g- and e-site products.
Apparent ratios
þGSM GSM
Mutation Ab 38/40 AICD 49–99/50–99 AICD 49–99/50–99
WT 2.1 1 1
A692G 1.54 1 1.02
E693G 1.26 1 1
D694N 1.61 1 0.91
T714I 3.6 0.22 0.17
V715A 3.6 0.21 0.21
I716V 1.5 0.72 0.71
V717F 1.46 o0.1 o0.1
L723P 2.25 o0.1 o0.1
Ratios are estimated from peak intensities determined by MALDI-TOF analysis, with respect to
Fig. 4.
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Rationalizing these results with structural models based on
molecular simulations of wild-type and mutant APP substrates,
we propose that the observed effects on Ab and AICD production
can be triggered by combined changes in the ﬂexibility, tilting
angle and positioning of both g- and e-sites in the membrane,
along with the hydration levels at the e-sites. Such structural
changes, by potentially modifying the presentation of the
substrates to the enzymatic complex, might affect the g-secretase
cleavage speciﬁcity. Consistent with this model, the elevated
Ab38/40 ratio observed in mutants T714I and V715A can be
explained by the vertical shift of the helix in the membrane
bilayer, with the consequent presentation of position 38 instead of
40 to the g-secretase cleavage site. The observed vertical shift in
mutants (B2.5 Å) is in fact associated with a tilting of half of a
helix turn (that is, displacement of two amino acids). Interest-
ingly, Ab38 and Ab42 have been proposed to originate from the
same sequential processing pathway, starting at the e-position 48,
and directly linked to AICD49–99 production15. Consistent with
this sequential model, we propose that the conformational
changes in the T714I and V715A substrates, associated with
reduced AICD50–99 levels, explain the preferential Ab38 and
Ab42 production observed with these mutants. Interestingly, and
apparently in contrast to the sequential cleavage model, the
V717F and L723P mutants, although characterized by reduced
AICD50–99 levels, do not show modiﬁcations in their Ab
proﬁles. This observation may reﬂect the existence of two or more
different pathological molecular explanations, classifying FAD
forms in different categories.
The nearly complete loss of AICD50–99 production in mutants
T714I, V715A, V71F and L723P, can plausibly be attributed,
according to our model, to higher solvation states around
positions 49 and 50, with the latter becoming more exposed to
water molecules. One can speculate that the increased water
accessibility to the leucine 49 may favour the cleavage at this
position, or inhibit the cleavage at valine 50 by preventing the
interaction at position 50 of APP-C99 with the hydrophobic trans-
membrane domain 1 of the g-secretase catalytic component PS1.
Possibly affecting the positioning of both APP g- and e-sites in
the membrane, cholesterol and the dimerization of APP have
recently been proposed to modulate the processing of APP-
TMD32,33. Although preliminary, our results (Supplementary Fig.
S8) suggest that when APP does not interact physically with
cholesterol molecules in a membrane made of POPCþ 15%
cholesterol, the dynamic properties of its TMD, including the
position of the Ab42 cleavage site, are the same as those of APP
inserted into a pure POPC membrane. Further investigation is
required to challenge this hypothesis, and examine whether both
cholesterol levels and APP dimerization parameters can affect the
dynamic properties of wt or FAD-APP TMDs.
Together, our data reported here provide new insights into the
therapeutic potential of chemical g-secretase modulators. They
are further expected to improve our current understanding of the
pathological mechanism of FAD.
Methods
c-Secretase inhibitors and modulators. g-Secretase inhibitors Compound E and
GSI XIX were purchased from Merck Millipore (Darmstadt, Germany). The
heteroaryl-type GSM E2012 (US2006/0004013) was obtained from Haoyuan
Chemexpress Co and the NSAID-type GSM-1 was synthesized at Syngene
according to methods described in WO2006/043064.
Molecular biology. The pET21b vector encoding the cDNAs of human APP-
C100-His was used as a template for the generation by PCR ampliﬁcation of all
His6-tagged FAD-APP-C100 mutants described in this study. The constructs were
expressed in BL21(DE3) cells induced with 1mM isopropyl-b-D-thiogalactopyr-
anoside (IPTG) for 4 h at optical density 600 nm¼ 0.8. For the puriﬁcation of APP-
C99 mutants, harvested bacteria were lysed with 10mM Tris (pH 7.0), 150mM
NaCl, 1% Triton X-100, protease inhibitor cocktail (PI; Roche, Rotkreuz,
Switerland), and passed through a high-pressure homogenizer (Emulsiﬂex-C5;
Avestin Inc., Mannheim, Germany). The obtained lysates were spun down at 5000g
for 30min and supernatants were incubated overnight with Ni-NTA agarose beads
(Invitrogen, Basel, Switzerland) at 4 C. Bound proteins were eluted in 1% NP-40
containing 250mM imidazole (pH 7.8), analysed by Coomassie-stained SDS–
PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis), and quantiﬁed
by bicinchoninic acid (BCA; Pierce, Rockford, Illinois, USA). The normalization
was validated by WB. Recombinant APP-C100-Flag and Notch N100-Flag sub-
strates were also expressed in BL21(DE3) cells, but 100mM glycine (pH 2.7)/1%
NP-40 was used for elution from M2-agarose beads.
APP-C100-Flag or APP-C100-His substrate consist of the b-CTF (C99) portion
of APP (residues 596-695) fused to C-terminal Flag- or His-tag. The Notch
cleavage assay used N100-Flag, a Notch-based substrate corresponding to residues
Val-1711 to Glu-1809 from murine Notch-1; this protein segment was also fused to
a C-terminal Flag-tag. For convenience in the text we have used APP-C99-Flag or
APP-C99-His and NotchDE-Flag.
Western blotting and antibodies. Samples from g-secretase activity assays were
run on 4–12% Bis-Tris gels and transferred onto PVDF membranes to detect Ab,
Flag-tagged APP- or Notch intracellular domain (AICD-Flag and NICD-Flag) with
Ab-speciﬁc 6E10 (1:1,000; Covance, Berkeley, California, USA) and Flag-speciﬁc
M2 antibodies (1:1,000; Sigma-Aldrich GmbH, Buchs, Switzerland). Anti-mouse/
rabbit/rat IgG conjugated to Alexa 680 were purchased from Invitrogen and the
Odyssey infrared imaging system (LICOR) was used to detect the ﬂuorescent
signal.
Whole cell extracts prepared in 50mM HEPES buffer containing 1% NP-40
were separated by electrophoresis on NuPAGE Novex 4–12% Bis-Tris Gels
(Invitrogen, Carlsbad, California, USA) for SDS–PAGE analysis, transferred onto
nitrocellulose membranes and probed with antibodies against APP-CTFs (Sigma-
Aldrich GmbH, Buchs, Switzerland.). For detection of NICD, membranes were
blocked with 5% milk and incubated overnight with primary antibody Val1744
anti-Notch (Cell Signaling, Bioconcept, Allchwil, Switzerland) at 4 C. Membranes
were washed with 1 TBST (1 TBSþ 0.1% Tween 20) for 15min and incubated
with HRP-conjugated secondary antibodies for 1 h at room temperature. Signal was
detected with Super Signal West chemiluminescent substrate (Thermo Scientiﬁc,
catalogue number 34077).
c-Secretase puriﬁcation. g-Secretase used in this study was composed of PS1,
Aph1aL, NCT and Pen-2, and was puriﬁed from 10 l of PB suspension cultures by
following the protocol described by Alattia et al.34
c-Secretase activity assays. g-Secretase assays using the recombinant APP- or
Notch-based substrates were performed as previously reported35. Brieﬂy, highly
puriﬁed g-secretase were solubilized in 0.2% (wt/vol) CHAPSO, 50mM HEPES
(pH 7.0), 150mM NaCl, 5mM MgCl2 and 5mM CaCl2, and incubated at 37 C for
4 h with 1 mM substrate, 0.1% (wt/vol) PC, 0.025% (wt/vol) PE. The resulting
products, APP intracellular domain AICD-Flag, AICD-His, Ab, and Notch
intracellular domain NICD-Flag were detected with above-described antibodies, or
analysed by mass spectrometry.
Immunoprecipitation-mass spectrometry analysis of Ab and AICD. Ab and
AICD generated in g-secretase in vitro assays with puriﬁed substrates were
analysed as previously described35. Brieﬂy, Ab was IP’d overnight using anti-Ab
antibody 4G8 (Covance, Berkeley, California, USA) and protein G coupled to
agarose resin (Roche Applied Science, Penzberg, Germany). For AICD or NICD
detection, 12ml 10% Triton X-100 solution was added after the enzymatic reaction
and incubated for 20min at 55 C prior to overnight immunoprecipitation at 4 C
with M2-anti Flag resin (Invitrogen) or Protein G (Roche, Mannheim, Germany),
coupled with anti-C-terminal AICD antibody. Ab and AICD-Flag were eluted with
1:20:20 (v:v:v) 1% (vol/vol) triﬂuoroacetic acid:acetonitrile:H2O, equally mixed with
saturated CHCA (a-cyano 4-hydroxy cinnaminic acid) for Ab, or sinapic acid for
AICD, and analysed by MALDI-TOF mass spectrometry in reﬂectron or linear
mode on an ABI 4800 MALDI-TOF/TOF mass spectrometer (Applied Biosystems,
Carlsbad, California, USA). Molecular masses were accurately measured and
searched against amino-acid sequences of human APP-C99 with addition of a
methionine residue at the N terminus and a Flag tag sequence (C100Flag) or a His-
tag sequence (C100His) at the C terminus, or a A692G, E693G, D654N, T714I,
V715A, I716V, V717F and L723P substitution.
MD simulations and molecular docking. We used MD simulations to
characterize the TM domain of WT and APP with FAD mutations. In a ﬁrst step,
the NMR structure (PDB code 2LP1 (ref. 27)) was inserted and equilibrated in a
60 60Å2 POPC patch36 to relax the structure in a phospholipid bilayer. The
system was solvated in 60 60 100Å2 water box, neutralized through the
addition of NaCl at a concentration of 150mM. After 30 ns, the equilibrated
structure was used as initial seed to build the other three mutants (V714A, T715I
and V717F) and WT-ligand complex. GSM-1 ligand was parameterized using
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CGenFF and ParamChem 0.9.6 (ref. 37). All MD simulations were performed using
NAMD 2.8 engine, with the CHARMM27 force ﬁeld, including CMAP corrections
for the protein and CHARMM36 for the POPC membrane38,39. TIP3P water
parameterization was used to describe the water molecules. The periodic
electrostatic interactions were computed using the particle-mesh Ewald (PME)
summation with a grid spacing o1Å. All systems were equilibrated for 30 ns at
300K. Free molecular dynamics were performed up to 100 ns with a 2 fs integration
time step using the RATTLE algorithm applied to all bonds. Constant temperature
(300 K) was imposed by using Langevin dynamics, with damping coefﬁcient of
1.0 ps. Constant pressure of 1 atm was maintained with a Langevin piston
dynamics, 200 fs decay period and 50 fs time constant.
GSM-1 was docked on WT and APP mutants using SWISSDock40,41 and
BSP-SLIM42; independently both approaches produced similar poses. As these
algorithms do not account for the presence of the membrane, we discarded all
unphysical docking poses, for example, the GSM-1 hydroxyl being buried in the
hydrophobic membrane core. The conformation with the lowest energy was then
selected for each system.
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